Junshi Biosciences Hits Primary Endpoints in Phase III NEOTORCH Study, Plans sNDA for Toripalimab

Why It Matters

The NEOTORCH trial’s success could reshape the standard of care for resectable NSCLC in China, a market that accounts for a quarter of the world’s lung‑cancer cases. By extending toripalimab’s perioperative label to stage II‑III disease, Junshi aims to address a sizable unmet need where recurrence rates remain high despite surgery and chemotherapy. The data also reinforce the broader shift toward integrating immunotherapy earlier in the treatment continuum, a strategy that may improve long‑term survival and reduce the economic burden of relapse. From an investment perspective, the expanded indication positions Junshi as a leading domestic player in the immuno‑oncology space, potentially attracting partnership interest from multinational firms seeking entry into China’s oncology market. The timing aligns with ASCO 2026, where investors will compare Junshi’s results with those of other biotech companies, influencing capital flows and valuation benchmarks across the sector.

Key Takeaways

• Junshi Biosciences reports primary endpoint success (EFS and MPR) in NEOTORCH Phase III trial of toripalimab plus chemotherapy.
• Study enrolled 501 patients with resectable stage II‑III NSCLC across multiple Chinese centers.
• Company will file a supplemental new drug application (sNDA) to expand perioperative approval to stage II‑III disease.
• Lung cancer accounts for 22% of new cancer cases and 28.5% of cancer deaths in China (2022 data).
• ASCO 2026 (May 29‑June 2, Chicago) will spotlight similar biotech developments, influencing investor sentiment.

Pulse Analysis

Junshi’s NEOTORCH results arrive at a pivotal moment for Chinese oncology. Historically, perioperative therapy in NSCLC has been dominated by cytotoxic regimens with modest survival gains. The integration of PD‑1 blockade, first demonstrated in metastatic settings, is now being validated in the curative intent space. Junshi’s data suggest that toripalimab can deliver a measurable boost in event‑free survival, a surrogate that regulators increasingly accept for accelerated approvals. If the sNDA clears, Junshi could capture a market segment that has been largely untapped, potentially generating upwards of $300 million in annual revenue within three years, assuming a conservative 15% market penetration.

The broader competitive landscape is intensifying. Companies like Merck (Keytruda) and Innovent (sintilimab) are also pursuing perioperative indications, and their ongoing trials will serve as comparators at ASCO 2026. Investors will be parsing efficacy nuances—hazard ratios, duration of response, safety signals—to gauge which agent offers the best risk‑benefit profile. Junshi’s advantage lies in its domestic manufacturing footprint and established relationships with Chinese hospitals, which could accelerate market uptake post‑approval.

Regulatory dynamics will be the next decisive factor. The NMPA has shown a willingness to grant expedited pathways for therapies that address high‑mortality diseases, but it also demands robust safety data, especially for neoadjuvant use where patients are otherwise healthy enough for surgery. Junshi’s ability to present comprehensive safety analyses alongside efficacy will determine whether the sNDA proceeds smoothly or encounters delays. In either scenario, the NEOTORCH outcome underscores a broader industry trend: moving immunotherapy earlier in the treatment algorithm, a shift that could redefine clinical trial design and reimbursement models for years to come.